Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
Department of Health and Human Services
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this NOFO must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or
Funding
Award size
$100K – $1M
Award ceiling
250000
Type
Cooperative Agreement
Dates
Deadline
Next 90 days
Posted
10/15/2024
Closes
2026-10-14
Eligibility
Eligibility
Public housing authorities/Indian housing authoritiesSmall businessesCounty governmentsPrivate institutions of higher educationState governmentsPublic and State controlled institutions of higher educationOthers (see text field entitled "Additional Information on Eligibility" for clarification)City or township governmentsNative American tribal governments (Federally recognized)Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher educationIndependent school districtsNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher educationFor profit organizations other than small businessesSpecial district governments
Program
Funding area
Education - EDHealth - HL
Opportunity #
PAR-25-075
Source
Status
Open
Market
Government
Level
Federal
Source
Grants.gov